Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

  • End date
    Jan 31, 2025
  • participants needed
  • sponsor
    Jonsson Comprehensive Cancer Center
Updated on 13 May 2022
platelet count
monoclonal antibodies
neutrophil count
tumor cells
soft tissue sarcoma
synovial sarcoma
undifferentiated pleomorphic sarcoma
sarcoma of the extremity
malignant peripheral nerve sheath tumor


This phase I trial studies the side effects of BO-112 when given together with nivolumab before surgery in treating patients with soft tissue sarcoma that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with BO-112, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab and BO-112 before surgery may work better in treating patients with soft tissue sarcoma compared to nivolumab alone.



I. To determine the safety and tolerability of integrating BO-112, and BO-112 with nivolumab in soft tissue sarcoma patients undergoing preoperative radiotherapy.


I. Determine the change in T cell infiltration at surgical resection from baseline as measured by immunohistochemistry.

II. Assess treatment effect (necrosis score) of BO-112 and BO-112 in combination with nivolumab in soft tissue sarcoma patients receiving preoperative hypofractionated radiotherapy, compared to patients treated on a recently completed phase 2 study of preoperative hypofractionated radiotherapy alone.

III. Evaluate the 2-year rate of local and distant metastasis of BO-112 and BO-112 in combination with nivolumab in patients with localized resectable soft tissue sarcoma receiving preoperative hypofractionated radiotherapy, as compared to historical patients receiving preoperative radiotherapy alone.


I. Evaluate the dynamics of the intratumoral T cell phenotype. II. Assess the capacity to grow ex vivo tumor infiltrating lymphocytes from patients treated with BO-112 and BO-112 in combination with nivolumab.

III. Analyze changes in T-cell receptor (TCR) repertoire in tumor infiltrating lymphocytes and peripheral blood mononuclear cells (PBMCs) between baseline, post-treatment, and ex vivo cultured tumor infiltrating lymphocyte (TIL) samples.

IV. For patients with disease burden outside of the resected lesion, assess imaging response to treatment using Response Evaluation Criteria in Solid Tumors (RECIST) criteria.


Patients receive BO-112 intratumorally on days 8 and 15 or 1, 8, and 15 and nivolumab intravenously (IV) over 30-60 minutes on day 8 in the absence of disease progression or unacceptable toxicity. Patients also undergo standard of care radiation therapy on days 8-12 for a total of 5 fractions. Patients then undergo standard of care definitive surgical resection on day 26 to 50.

After completion of study treatment, patients are followed up at 2 weeks, 3 months, and between 6-12, 12-18, and 18-24 months.

Condition Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Myxofibrosarcoma, Pleomorphic Rhabdomyosarcoma, Resectable Dedifferentiated Liposarcoma, Resectable Soft Tissue Sarcoma, Resectable Undifferentiated Pleomorphic Sarcoma, Soft Tissue Fibrosarcoma, Spindle Cell Sarcoma, Stage I Retroperitoneal Sarcoma AJCC (American Joint Committee on Cancer) v8, Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IA Retroperitoneal Sarcoma AJCC v8, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IB Retroperitoneal Sarcoma AJCC v8, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage II Retroperitoneal Sarcoma AJCC v8, Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage III Retroperitoneal Sarcoma AJCC v8, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIA Retroperitoneal Sarcoma AJCC v8, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIB Retroperitoneal Sarcoma AJCC v8, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Storiform-Pleomorphic Malignant Fibrous Histiocytoma, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Undifferentiated Pleomorphic Sarcoma, Undifferentiated Pleomorphic Sarcoma With Osteoclast-Like Giant Cells, Undifferentiated Pleomorphic Sarcoma, Inflammatory Variant, Undifferentiated Spindle Cell Sarcoma
Treatment radiation therapy, Nivolumab, Definitive Surgical Resection, Immunotherapeutic Agent, Nanoplexed Poly I:C BO-112
Clinical Study IdentifierNCT04420975
SponsorJonsson Comprehensive Cancer Center
Last Modified on13 May 2022


Yes No Not Sure

Inclusion Criteria

Written informed consent, and assent where appropriate, must be obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
Biopsy proven soft tissue sarcoma of the extremity, trunk or retroperitoneum including undifferentiated pleomorphic sarcoma, myxofibrosarcoma, leiomyosarcoma, dedifferentiated liposarcoma, synovial sarcoma, malignant peripheral nerve sheath tumor, or pleomorphic rhabdomyosarcoma. Undifferentiated pleomorphic sarcoma encompasses any of the following histologies
Pleomorphic undifferentiated sarcoma
Unclassified spindle cell sarcoma
Spindle cell sarcoma not otherwise specified
Pleomorphic spindle cell sarcoma
Pleomorphic fibroblastic sarcoma
Undifferentiated high-grade pleomorphic sarcoma
Pleomorphic sarcoma with prominent inflammation
Pleomorphic sarcoma with giant cells
Malignant fibrous histiocytoma (including storiform-pleomorphic and inflammatory subtypes)
Tumor that is injectable
Hemoglobin >= 9 g/dL
Absolute neutrophil count >= 1,000/mm^3
Platelet count >= 100,000/mm^3 and transfusion independent
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (ULN)
Bilirubin =< 1.5 x ULN; for subjects with documented/suspected Gilbert's disease, bilirubin =< 3 x ULN
Serum creatinine < 1.5 x ULN or creatinine clearance > 60 mL/min for patients with creatinine levels above ULN (as determined by Cockcroft-Gault equation)
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5 x institutional upper limit of normal unless the patient is on anticoagulant therapy within 28 days prior to enrollment (if the patient is receiving anticoagulant therapy, PT, and a PTT must be within therapeutic range of intended use of anticoagulants)
Patients must be willing to submit blood and tissue specimens for translational medicine studies
Patients must be offered the opportunity to participate in specimen banking for future research
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of study drug
Women must not be breastfeeding
Women of childbearing potential (WOCBP) must be willing to use either two adequate barrier methods or a barrier method plus a hormonal method of contraception to prevent pregnancy, or to abstain from heterosexual activity (complete abstinence) throughout the study, starting with visit 1 through 5 months after the last dose of study therapy. Approved contraceptive methods include intrauterine device, diaphragm with spermicide, cervical cap with spermicide, male condoms, female condoms with spermicide, or oral contraceptives. Spermicides alone are not an acceptable method of contraception. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to highly effective contraception during active participation in study treatment and for a period of 7 months after the last dose of nivolumab
Progestogen only hormonal contraception associated with inhibition of ovulation
Highly effective methods of contraception have a failure rate of < 1% when used
consistently and correctly. WOCBP and female partners of male subjects, who are WOCBP, are
Nonhormonal IUDs, such as ParaGard
expected to use one of the highly effective methods of contraception listed below. Male
Bilateral tubal occlusion
subjects must inform their female partners who are WOCBP of the contraceptive requirements
Vasectomized partner with documented azoospermia 90 days after procedure
of the protocol and are expected to adhere to using contraception with their partner
Contraception methods are as follows
Intrauterine hormone-releasing system (IUS)
Complete abstinence
Hormonal methods of contraception including oral contraceptive pills containing
combined estrogen + progesterone, vaginal ring, injectables, implants and intrauterine
devices (IUDs) such as Mirena
Vasectomized partner is a highly effective birth control method provided that
partner is the sole sexual partner of the WOCBP trial participant and that the
Diaphragm with spermicide
vasectomized partner has received medical assessment of the surgical success
Cervical cap with spermicide
Vaginal sponge with spermicide
Male or female condom with or without spermicide
Complete abstinence is defined as the complete avoidance of heterosexual
A male and a female condom must not be used together
Complete abstinence is an acceptable form of contraception for all study drugs
and must be used throughout the duration of the study treatment (plus 5
Periodic abstinence (calendar, symptothermal, post-ovulation methods)
half-lives of the investigational drug plus 30 days)
Withdrawal (coitus interruptus)
It is not necessary to use any other method of contraception when complete
Spermicide only
abstinence is elected
Lactation amenorrhea method (LAM)
Subjects who choose complete abstinence must continue to have pregnancy tests, as
Acceptable alternate methods of highly effective contraception must be discussed
in the event that the subject chooses to forego complete abstinence
The reliability of sexual abstinence needs to be evaluated in relation to the
duration of the clinical trial and the preferred and usual lifestyle of the
Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the
primary mode of action

Exclusion Criteria

Women who are pregnant or breastfeeding
Inability to give informed consent
History of other malignancy that can interfere with interpretation of the results
Active or prior documented autoimmune disease within the past 3 years
Active or prior documented inflammatory bowel disease
Prisoners or subjects who are involuntarily incarcerated
Contraindications to tumor biopsy and injections (coagulopathy, known history of
keloid formation, etc.)
Prior irradiation in the area to be treated with preoperative radiation such that the
risk of re-irradiation outweighs its benefit, according to the treating radiation
Any condition that might interfere with the subject's participation in the study
safety, or in the evaluation of the study results
Concurrent enrollment in another clinical study, unless it is an observational
(non-interventional) clinical study or the follow-up period of an interventional study
Patients must not have received any live vaccine within 30 days prior to registration
Seasonal flu vaccines and other vaccines that do not contain live virus are permitted
Any concurrent chemotherapy, immunotherapy, or biologic therapy for cancer treatment
Concurrent use of hormones is acceptable
Patient must not have evidence of any clinically significant immunosuppression such as
the following: primary immunodeficiency state such as severe combined immunodeficiency
disease; concurrent opportunistic infection; receiving systemic immunosuppressive
therapy within 28 days before enrollment with the exceptions of intranasal, topical
and inhaled corticosteroids or oral corticosteroids at physiologic doses not to exceed
mg/day of prednisone or equivalent
NOTE: Subjects with active, known or suspected autoimmune disease such as
vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune
condition only requiring hormone replacement, psoriasis not requiring systemic
treatment, or conditions not expected to recur in the absence of an external
trigger are permitted to enroll
History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required
steroids or has current ILD/pneumonitis or where suspected ILD/pneumonitis cannot be
ruled out by imaging at screening
Current or history of fibromyalgia, myositis, myocarditis or myasthenia gravis
Exposure to any investigational drug within 7 days prior to screening visit or for
which 5 half-lives have not elapsed
Note: under certain specific circumstances a person who has been imprisoned may
be included or permitted to continue as a subject
Subjects who are compulsorily detained for treatment of either a psychiatric or
physical (e.g., infectious disease) illness
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note